Abstract
Background The global urgency for effective treatments against SARS-CoV-2 infections, causing COVID-19, remains paramount. One promising avenue is repurposing existing medications. IMU-838, a dihydroorotate dehydrogenase (DHODH) inhibitor, has exhibited potent antiviral effects against respiratory viruses. In rodent studies, its combined administration with oseltamivir has shown therapeutic potential against both influenza and SARS-CoV-2.
Objective The primary aim of the IONIC pilot feasibility trial was to comprehensively explore the feasibility and safety challenges associated with administering the novel treatment regimen of IMU-838 combined with oseltamivir to COVID-19 patients. The secondary objective was to evaluate whether a 14-day treatment course with IMU-838 and oseltamivir improves time to clinical improvement compared to oseltamivir alone, defined as the duration from randomization to achieving a 2-point improvement on the WHO ordinal scale, discharge from the hospital, or occurrence of death, whichever comes first.
Methods IONIC was a Phase IIb, randomised, open-label, single centre trial. Prospective participants were recruited from a single centre within the UK and were eligible if they had moderate to severe COVID-19 requiring hospitalisation, were aged 18 years or above. Patients were randomly assigned, in a 1:1 ratio, to either the IONIC intervention arm (IMU-838 + oseltamivir + standard care) or the control arm (oseltamivir + standard care). Sponsored by the University Hospital Coventry & Warwickshire NHS Trust and funded by LifeArc, the trial comprises two distinct phases: a pilot feasibility study and a main study. The aim of the feasibility study was to inform the design and execution of the main study. However, due to recruitment challenges, the main study was not conducted. The present paper reports the results of the feasibility study. The trial was prospectively registered with ISRCTN (ISRCTN53038326) and Clinicaltrials.gov (NCT04516915)
Findings Between 22 Jun 2020 and 20th May 2022, 38 participants were recruited into the trial. Recruitment challenges hindered the main study, but the feasibility trial provided encouraging findings. Treatment completion rates stood at 84%, with no serious adverse effects observed affirming the safety profile of the novel treatment. Although no statistically significant difference emerged in time to clinical improvement between the treatment and control groups, logistic regression analysis indicated a notable association between the treatment group and clinical improvement within a 14-day window. These results emphasize the crucial role of feasibility studies in guiding larger-scale trials and underscore the necessity for further investigation into the therapeutic potential of this approach to the treatment of COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04516915
Funding Statement
The study has received funding from LifeArc organisation (grant-COVID-19 call/no award number)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The trial adhered to Good Clinical Practice and the Declaration of Helsinki guidelines, with ethics approval obtained from Wales Research Ethics Committee (Ref No: 20/WA/0146). In addition, required regulatory approvals were received from the Medicines and Healthcare products Regulatory Agency (MHRA).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
